Back to News
Market Impact: 0.2
Cognition's Q3 Loss Declines To $4 Mln As Phase 3 For Zervimesine In Dementia Set To Begin
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Cognition Therapeutics reported a lower loss for the third quarter, attributing the improvement to increased income. The brief report provides no financial figures or additional outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
CGTX0.30
More News
- Binance CFO exits days after catastrophic $6 billion crypto hack
- Decisive election. Dramatic stock swings. How we handled the market last week
- Berkshire Hathaway more than doubles buybacks in third quarter as earnings decline
- Berkshire shares surge as Wall Street swoons amid AI fears
- Paraguay’s ousted president charged over banking scandal
- CoreWeave seeks truce with Texas Governor-elect Hinojosa